Table 1. The relationship between clinicopathological characteristics and serum biomarkers concentrations.

(Mean and 95% CI).

	n	CA125	P v		CA15-3	P v	CRP	P v	D-D	P v	PLR	P v	NLR	P v
		(U/ml)			(U/ml)		(mg/l)		(mg/l)
Age
<50	98	23.82		0.491	12.92	0.336	1.13	0.002	0.55	0.286	147.64	0.001	2	0.257
		(14.08–46.81)			(9.14–19.89)		(0.46–2.89)		(0.40–0.90)		(113.36–208.92)		(1.52–2.74)
≥50	184	21.11			12.19		2.17		0.6		125.1		1.83
		(14.07–39.90)			(8.88–17.71)		(0.72–6.19)		(0.40–1.00)		(99.13–165.96)		(1.38–2.69)
Type
Ⅰ	254	132.18		0.708	21.67	0.787	6.42	<0.001	1.34	0.349	148.87	0.008	2.29	<0.001
		(41.11–223.23)			(14.04–29.31)		(3.59–9.34)		(0.45–2.23)		(140.15–157.96)		(2.11–2.46)
Ⅱ	28	79.55			24.91		33.62		2.65		191.45		3.88
		(35.68–123.28)			(7.81–42.01)		(13.79–53.46)		(1.22–4.08)		(137.34–245.57)		(2.51–5.25)
FiGO
Ⅰ	152	18.73		<0.001	10.97	<0.001	1.33	0.003	0.5	<0.001	126.47	0.365	1.8	0.054
		(13.31–25.62)			(7.80–15.59)		(0.54–4.20)		(0.30–0.73)		(106.33–167.91)		(1.37–2.46)
Ⅱ	58	25.53			12.37		1.33		0.6		129.33		1.9
		(15.93–46.99)			(9.37–19.35)		(0.58–4.70)		(0.45–0.90)		(99.03–200.59)		(1.46–2.88)
Ⅲ	61	44.41			15.99		3.07		0.9		139.07		2.08
		(20.65–72.30)			(10.84–29.3)		(0.82–10.43)		(0.50–1.70)		(104.76–185.46)		(1.52–3.47)
Ⅳ	11	93.19			27.93		3.17		1.4		155		2.84
		(57.93–386.90)			(10.27–43.3)		(2.28–29.68)		(0.65–2.45)		(111.20–255.14)		(1.60–3.20)
Grade
G1	69	17.75		0.001	11.16	0.003	1.11	0.011	0.5	<0.001	145	0.124	2.1	0.126
		(13.22–23.01)			(7.45–15.21)		(0.45–3.27)		(0.30–0.90)		(114.94–195.72)		(1.30–2.55)
G2	145	25.08			13.07		1.7		0.55		129.5		1.76
		(13.73–44.66)			(9.25–19.01)		(0.68–4.83)		(0.40–0.80)		(101.95–167.49)		(1.44–2.60)
G3	68	26.07			13.82		2.67		0.9		122.73		2.18
		(15.75–62.43)			(9.70–24.82)		(0.81–12.19)		(0.50–1.70)		(101.09–205.83)		(1.49–3.32)
Metas.
Yes	14	20.51		0.689	14.26	0.97	4.96	0.019	1	0.021	138.71	0.522	2.3	0.231
		(11.86–59.16)			(7.28–23.54)		(1.05–48.76)		(0.65–1.73)		(108.04–243.000)		(1.40–4.63)
No	268	21.54			12.47		1.49		0.6		130		1.89
		(14.09–44.40)			(9.12–18.99)		(0.58–4.94)		(0.40–0.90)		(105.14–177.72)		(1.43–2.67)
Recur.
Yes	12	17.37		0.994	11.38	0.808	11.14	0.001	0.7	0.081	140.35	0.384	2.9	0.031
		(9.62–274.60)			(7.55–50.66)		(2.38–63.18)		(0.50–4.10)		(92.98–332.45)		(1.85–5.09)
No	270	21.47			12.5		1.47		0.6		130.25		1.88
		(14.13–41.76)			(9.10–18.83)		(0.59–4.83)		(0.40–1.00)		(105.94–177.31)		(1.42–2.67)

P-v: p value; Type: types of endometrial carcinoma; FIGO: the FIGO stage; Grade: Histopathological grade; D-D: D dimer; PLR: platelet to lymphocyte ratio; NLR: neutrophil to lymphocyte ratio; Metas.: metastasis; Recur.: recurrence